New Oral GLP-1 Options in the Pipeline: What's Coming and When

For a long time, all GLP-1 medications required weekly injections. That changed with the approval of oral semaglutide, and a wave of new oral options is now in development. For people who are needle-averse or simply want more options, this is exciting news.

Oral Semaglutide: Already Here

Rybelsus^®, Novo Nordisk’s oral semaglutide, has been available for type 2 diabetes since 2019. However, its use has been limited by its strict administration requirements: It must be taken on an empty stomach with a small amount of water, and you have to wait 30 minutes before eating or taking other medications. Even with perfect adherence, it achieves lower blood levels than injectable semaglutide.

More recently, Novo Nordisk developed a higher-dose oral semaglutide tablet (25 mg) specifically for weight management, now approved by the FDA under the Wegovy^® brand name. In the OASIS 4 trial, the once-daily pill demonstrated weight loss comparable to injectable Wegovy^® 2.4 mg, and it became available in the U.S. in early January 2026.

As with injectable GLP-1 medications, gastrointestinal side effects such as nausea, vomiting, and diarrhea remain the most commonly reported adverse reactions with oral formulations. Patients should discuss their full medical history with a provider before starting any GLP-1 medication.

Orforglipron: A Different Approach

One of the most-watched candidates is orforglipron, a small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide and tirzepatide, which are peptide-based drugs derived from biological molecules, orforglipron is chemically synthesized and may be easier and cheaper to manufacture at scale.

Importantly, orforglipron does not have the same strict food restrictions as oral semaglutide, which could make it significantly more convenient. Multiple Phase 3 clinical trials have reported positive results, and Lilly has submitted orforglipron to the FDA for review, with a decision expected in early-to-mid 2026.

Why Oral Options Matter

Expanding beyond injectable medications could significantly increase the number of people willing to try GLP-1 therapy. Needle phobia is a real barrier for many patients. Oral medications also tend to feel more “normal” to people who are new to treatment, potentially improving adherence. Additionally, simpler-to-manufacture oral drugs could eventually lower costs, one of the biggest barriers to access.

The Caveat: We’re Not There Yet

Oral GLP-1 options have advanced rapidly, but the landscape is still evolving. The newly available Wegovy^® pill has demonstrated weight loss comparable to its injectable counterpart, and additional oral candidates are nearing regulatory decisions. Still, timelines for approval are never guaranteed, and long-term real-world data on newer oral formulations will take time to accumulate.

Where Oral GLP-1 Therapy Stands Now

The era of injection-only GLP-1 therapy is starting to evolve. Over the next several years, we’re likely to see more oral options, both improved versions of existing drugs and entirely new molecules, that could make GLP-1 therapy more accessible, convenient, and affordable for a much broader population.

The FDA-approved GLP-1 receptor agonist medications discussed in this article are prescription medications for specific indications: semaglutide (Ozempic®) for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and cardiovascular disease; semaglutide (Wegovy®) for chronic weight management; tirzepatide (Mounjaro®) for type 2 diabetes; and tirzepatide (Zepbound®) for chronic weight management. This article is for educational and informational purposes only and does not constitute medical advice. Individual results may vary. Consult your healthcare provider to determine if GLP-1 therapy is appropriate for your individual health situation and to discuss potential risks, side effects, and contraindications.

Writing Staff